score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability - High	Guideline			Somatic Variant	PDGFRA	Missense	p.E141K	0.177	243.0	0.0	0.0		Investigate Actionability - High	Imatinib	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf												0				PDGFRA p.E141K (Missense)	0.0	MEL-IPI_Pat59	MEL-IPI_Pat59-Tumor-SM-4DK2K	MEL-IPI_Pat59-Normal-SM-4NFVQ
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																							0				Supporting variants: PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat59		
Biologically Relevant				Mutational Signature	COSMIC Signature 7		0.75																							0				COSMIC Signature 7 (75%)		MEL-IPI_Pat59		
